Francesco Bertoni

Articolo pubblicato in rivista scientifica (7)

• Spriano F., Tarantelli C., Cascione L., Gaudio E., Golino G., Scalise L., Cacciapuoti M. T., Zucca E., Stathis A., Van Berkel P. H., Inghirami G., Zammarchi F., Bertoni F. (2024) Targeting CD25+ lymphoma cells with the antibody-drug conjugate camidanlumab tesirine as a single agent or in combination with targeted agents, British journal of haematology, 205 (5)
• Zucca E., Rossi D., Bertoni F. (2023) Marginal zone lymphomas, Hematological Oncology, 41 (S1)
• Chung E. Y. L., Sartori G., Ponzoni M., Cascione L., Priebe V., Xu-Monette Z. Y., Fang X., Zhang M., Visco C., Tzankov A., Rinaldi A., Sgrignani J., Zucca E., Rossi D., Cavalli A., Inghirami G., Scott D. W., Young K. H., Bertoni F. (2023) ETS1 phosphorylation at threonine 38 is associated with the cell of origin of diffuse large B cell lymphoma and sustains the growth of tumour cells, British journal of haematology, 203 (2)
• Guidetti F., Arribas A. J., Sartori G., Spriano F., Barnabei L., Tarantelli C., Von Roemeling R., Martinez E., Zucca E., Bertoni F. (2023) Targeting IRAK4 with emavusertib in lymphoma models with secondary resistance to PI3K and BTK inhibitors, Journal of Clinical Medicine, 12 (2)
• Tarantelli C., Bertoni F. (2022) United we stand. Double targeting of CD79B and CD20 in diffuse large B-cell lymphoma, British Journal of Haematology, 199
• Munz N., Guidetti F., Bertoni F. (2022) Enhancer RNAs (eRNAs) in cancer. The jacks of all trades, Cancers, 14 (8)
• Tarantelli C., Argnani L., Zinzani P. L., Bertoni F. (2021) PI3Kδinhibitors as immunomodulatory agents for the treatment of lymphoma patients, Cancers, 13